Currently available GLP-1 receptor agonists in the UK include: For type 2 diabetes : semaglutide (Ozempic [injection], Rybelsus [oral tablet]), dulaglutide (Trulicity), liraglutide (Victoza), exenatide (Byetta, Bydureon), and lixisenatide (Lyxumia) For weight management : semaglutide 2.4 mg (Wegovy) and liraglutide 3 mg (Saxenda) Most GLP-1 medications are administered via subcutaneous injection, with dosing frequencies ranging from daily to once weekly depending on the specific formulation
Contact your GP if cold sensitivity is severe or persistent, or if accompanied by extreme fatigue, hair loss, unexplained weight gain, breathlessness, or colour changes in hands and feet, as these may indicate thyroid dysfunction, anaemia, or circulatory problems requiring investigation
Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinsons disease
Without such protection, almost all of the peptide would degrade before it could act
For individuals struggling with obesity, Semaglutide can be an effective treatment option
They provide fluid while also helping you meet your daily protein goals, making them especially useful on busy mornings, after exercise, or on days when eating a full meal feels difficult
